BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
2.880
+0.010 (0.35%)
Apr 25, 2025, 4:00 PM EDT - Market closed

BioNexus Gene Lab Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2016 - 2019
Period Ending
Apr '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
Market Capitalization
559165365236
Upgrade
Market Cap Growth
-46.33%-46.33%-94.33%-54.75%54.35%-
Upgrade
Enterprise Value
113164363236
Upgrade
Last Close Price
2.882.805.30114.00255.60276.00
Upgrade
PE Ratio
----485.24215.96
Upgrade
PS Ratio
0.540.530.9615.1027.2920.74
Upgrade
PB Ratio
0.620.600.9724.7650.8035.47
Upgrade
P/TBV Ratio
0.620.600.9724.7650.8035.47
Upgrade
P/FCF Ratio
---331.6260792.561802.86
Upgrade
P/OCF Ratio
---299.0739809.47427.52
Upgrade
EV/Sales Ratio
0.110.120.3414.9727.1720.69
Upgrade
EV/EBITDA Ratio
----316.52358.35
Upgrade
EV/EBIT Ratio
----343.88415.74
Upgrade
EV/FCF Ratio
---328.7460523.491798.18
Upgrade
Debt / Equity Ratio
0.030.030.020.010.010.02
Upgrade
Debt / EBITDA Ratio
----0.070.19
Upgrade
Debt / FCF Ratio
---0.1112.830.94
Upgrade
Asset Turnover
0.870.870.971.191.362.01
Upgrade
Inventory Turnover
6.516.517.987.748.2316.34
Upgrade
Quick Ratio
3.103.104.242.522.392.02
Upgrade
Current Ratio
3.813.814.933.013.072.37
Upgrade
Return on Equity (ROE)
-17.78%-17.78%-32.21%-5.14%10.86%28.11%
Upgrade
Return on Assets (ROA)
-10.86%-10.86%-18.85%-1.50%6.70%6.25%
Upgrade
Return on Capital (ROIC)
-12.92%-12.92%-22.98%-1.97%9.40%8.86%
Upgrade
Return on Capital Employed (ROCE)
----14.60%8.40%
Upgrade
Earnings Yield
-30.89%-31.80%-28.08%-0.22%0.21%0.46%
Upgrade
FCF Yield
-47.57%-48.98%-21.05%0.30%0.00%0.06%
Upgrade
Buyback Yield / Dilution
-12.24%-12.24%-10.17%-0.99%-66.36%-19.16%
Upgrade
Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q